NCT01009918
Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab
See it on ClinicalTrials.gov ↗468 people
100%
468 womenmiddle line = equal numbers0 men
- Phase
- PHASE2
- Paid for by
- University of South Florida
- Finished
- 2018-11
- Health conditions
- Breast Cancer, Cardiac Toxicity
- Who could join
- Anyone
- Ages
- 18 Years – no maximum
- Average age
- mean 51.09 Years
- Age 65+
- Not reported
- Weight (BMI)
- mean 28.43 kg/m^2
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- White 86.3% · Black / African American 7.3% · Asian 2.6% · Not reported 2.1% · American Indian / Alaska Native 0.9% · More than one race 0.6% · Native Hawaiian / Pacific Islander 0.2%
Women left out
- No pregnant women
Women who were pregnant could not join.
“Not pregnant or breastfeeding”
- Had to use birth control
Women who couldn't or didn't want to use birth control were turned away.
“Both men and women must be willing to use effective contraception during the study. Teratogenicity is documented for both active study agents”
- No heart disease
Women with heart disease, heart rhythm problems or a past heart attack were turned away.
“Known cardiac history: heart failure, myocardial infarction, radiation-induced cardiac dysfunction”
Study titles and rules are shown in their original English.